Nontuberculous Mycobacterial Infections Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, Japan, China - Size and Forecast 2024-2028

Published: Dec 2023 Pages: 177 SKU: IRTNTR77103

Nontuberculous Mycobacterial (NTM) Infections Market 2024-2028

The global nontuberculous mycobacterial (NTM) infections market size is estimated to grow by USD 4.33 billion at a CAGR of 5.66% between 2023 and 2028. 

As awareness among healthcare professionals and the broad public about nontuberculous mycobacterial infections rises, there is a parallel increase in the number of diagnosed cases. This heightened awareness leads to earlier detection and intervention, which has a positive impact on patient outcomes, thereby propelling the demand for effective treatments for NTM infections. Health education campaigns and awareness programs play a vital role in disseminating information about NTM infections, their risk factors, symptoms, and the significance of timely diagnosis and treatment. Moreover, several programs contribute to the awareness of NTM infections. One notable initiative is the NTM Info and Research organization, which focuses on providing information, resources, and support to individuals affected by NTM infections. Thus, such awareness programs will drive the growth of the market during the forecast period.

Technavio has segmented the market into Distribution Channel, Product, and Geography 

  • The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies
  • The product segment includes clarithromycin, azithromycin, rifampin, rifabutin, and others
  • The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Nontuberculous Mycobacterial Infections Market During the Forecast Period?

To learn more about this report, Download Report Sample

Nontuberculous Mycobacterial Infections Market Segmentation by Distribution Channel, Product, and Geography  Analysis

Distribution Channel Analysis 

Hospital pharmacies 

The market share growth by the hospital pharmacies segment will be significant during the forecast period. Hospital pharmacies serve as essential mediators in the distribution of pharmaceutical drugs, including antibiotics and other medications utilized to treat NTM infections. Hospital pharmacies work closely with suppliers and pharmaceutical companies to procure the required NTM infection-related drugs. Hospital pharmacies keep records of the medications that are dispensed to each patient. This assists in tracking the patient's treatment progress and ensures accountability. 

Get a glance at the market contribution of various segments Download PDF Sample

The hospital pharmacies segment was valued at USD 4.97 billion in 2018. Furthermore, hospital pharmacies contribute to patient education, offering guidance on the need for medication adherence and potential drug interactions. The comfort of getting specified medications within the hospital/healthcare setting improves patient compliance with the treatment regimen, which is important for the effective management of NTM infections. Thus, such factors will drive the growth of the hospital pharmacies segment, which will drive the growth of the nontuberculous mycobacterial (NTM) infections market during the forecast period.

Product Segment Analysis

Clarithromycin

Clarithromycin, a macrolide antibiotic, is adored for its ability to inhibit bacterial protein synthesis, making it very effective in treating NTM infections. Clarithromycin exhibits a wide spectrum of activity against different NTM strains, making it a versatile choice in the treatment of these infections. Clinical guidelines usually recommend Clarithromycin as part of combination therapy for NTM infections, further driving its adoption in the healthcare industry. Moreover, with the rising prevalence of NTM infections globally, particularly among immunocompromised individuals, the demand for effective antibiotics like Clarithromycin is on the pitch. Therefore, such factors will fuel the growth of the Clarithromycin segment of the nontuberculous mycobacterial infections market during the forecast period.

Azithromycin

The Azithromycin product type segment plays a vital role in the treatment of NTM infections owing to its effectiveness in treating mycobacterial infections. Azithromycin, a macrolide antibiotic, has shown efficacy against various strains of NTM, making it the best choice in the pharmaceutical arsenal for combating these infections.  Azithromycin is available in different formulations, including oral tablets and suspensions, which provide convenient administration and lead to better patient compliance. Clinical guidelines often recommend Azithromycin as part of a combination therapy for NTM infections. Thus, such factors will drive the growth of the Azithromycin segment of the NTM infections nontuberculous mycobacterial infections market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The rising prevalence of NTM infections in North America, particularly among individuals with underlying respiratory conditions or compromised immune systems, is a significant driver. North America brags a refined healthcare infrastructure with state-of-the-art diagnostic abilities and a well-established pharmaceutical industry. The availability of state-of-the-art diagnostic tools and the powerful capacity for clinical research contribute to the identification and understanding of NTM infections, facilitating the development and adoption of novel therapies.

In addition, the region's robust R&D ecosystem plays a key role in driving innovation in NTM treatments. Furthermore, pharmaceutical companies and educational institutions are actively employed in clinical trials, researching new drug candidates, combination therapies, and accurate medicine procedures to handle the challenges posed by NTM infections. Thus, such factors will drive the growth of the nontuberculous mycobacterial (NTM) infections market in North America during the forecast period.

Buy Full Report Now

Key Nontuberculous Mycobacterial Infections Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 17 market companies, including:

Astellas Pharma Inc.: The company offers nontuberculous mycobacterial infection drug namely ASTAGRAF XL.

  • Abbott Laboratories
  • Cipla Ltd.
  • Dr Reddys Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals Plc
  • Insmed Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Pace Biotech, Pfizer Inc.
  • QIAGEN NV
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Nontuberculous Mycobacterial Infections Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Nontuberculous Mycobacterial Infections Market Drivers

The growing prevalence of NTM globally is the key factor driving market growth. According to the National Institutes of Health (NIH), from 2006 to 2021, the majority of NTM infections in individuals with non-CF bronchiectasis was expected to be around 10% worldwide, with considerable regional differences. The most prevalent subspecies was MAC, which was followed by Mycobacterium simiae and Mycobacterium gordonae. NTM infections are an emerging public health problem across the globe. Furthermore, the factors contributing to the rising prevalence of NTM infections include heightened awareness of these infections, improved diagnostic techniques, and an expanding population of immunocompromised individuals.

Moreover, as the prevalence of NTM infections continues to escalate worldwide, there is a growing demand for effective diagnostic tools and therapeutic interventions. In addition, pharmaceutical companies are actively employed in R&D to address this demand, leading to the introduction of new drugs and treatment modalities. This heightened focus on NTM infections, driven by their increasing prevalence, is expected to drive the growth of the global nontuberculous mycobacterial infections market during the forecast period. 

Significant Nontuberculous Mycobacterial Infections Market Trends

The growing adoption of precision medicine for the treatment of NTM infections is the primary trend shaping market growth. Advances in genomic technologies allow a more exhaustive understanding of the genetic makeup of NTM strains. This knowledge facilitates the identification of specific molecular targets for drug development, allowing the creation of more effective and tailored therapies. Precision medicine enables healthcare providers to develop personalized treatment plans based on the individual patient's genetic profile and the characteristics of the infecting NTM strain.

Furthermore, collaborations between pharmaceutical companies, research institutions, and precision medicine-focused organizations are aimed at developing innovative therapies that align with the principles of precision medicine. Consequently, the introduction of precision medicine into the treatment of NTM infections will propel the growth of the market during the forecast period.

Major Nontuberculous Mycobacterial Infections Market Challenges

The heterogeneity of NTM strains is a challenge that affects market growth. NTM comprises a diverse group of mycobacteria species, each with unique characteristics, including varying antimicrobial susceptibilities. This heterogeneity complicates treatment approaches in several ways. Firstly, the diverse nature of NTM strains requires tailored treatment regimens, as different species may respond differently to the same antibiotics. This complexity inhibits the development of standardized, one-size-fits-all treatment protocols, making it challenging for healthcare providers to guide and prescribe effective therapies. 

Also, the variability in clinical presentations and disease progression among patients infected with different NTM strains adds another layer of complexity. Tailoring the treatment based on the specific NTM strain and individual patient needs becomes crucial for achieving optimal outcomes, but heterogeneity impedes the establishment of standardized guidelines. Hence, the heterogeneity of NTM strains will impede the growth of the market during the forecast period.

Buy Now Full Report

Key Nontuberculous Mycobacterial Infections Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Nontuberculous Mycobacterial Infections Market Customer Landscape

Segment Overview

The nontuberculous mycobacterial infections market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028. 

  • Distribution Channel Outlook
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
  • Product Outlook
    • Clarithromycin
    • Azithromycin
    • Rifampin
    • Rifabutin
    • Others
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Brazil 
      • Argentina
      • Australia

Nontuberculous Mycobacterial Infections Market Scope

Report Coverage

Details

Page number

177

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 5.66%

Market growth 2024-2028

USD 4.33 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

5.25

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, UK, Germany, Japan, and China

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, Astellas Pharma Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Insmed Inc., Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Pace Biotech, Pfizer Inc., QIAGEN NV, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Nontuberculous Mycobacterial Infections Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the nontuberculous mycobacterial infections market between 2024 and 2028
  • Precise estimation of the nontuberculous mycobacterial infections market size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of nontuberculous mycobacterial infections market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global nontuberculous mycobacterial infections market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global nontuberculous mycobacterial infections market 2018 - 2022 ($ billion)
    • 4.2 Distribution Channel Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ billion)
    • 4.3 Product Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Product Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 32: Chart on Comparison by Distribution Channel
      • Exhibit 33: Data Table on Comparison by Distribution Channel
    • 6.3 Hospital pharmacies - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.4 Retail pharmacies - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.5 Online pharmacies - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Distribution Channel
      • Exhibit 46: Market opportunity by Distribution Channel ($ billion)
      • Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 48: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Exhibit 50: Chart on Comparison by Product
      • Exhibit 51: Data Table on Comparison by Product
    • 7.3 Clarithromycin - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Clarithromycin - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Clarithromycin - Year-over-year growth 2023-2028 (%)
    • 7.4 Azithromycin - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Azithromycin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Azithromycin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Azithromycin - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Azithromycin - Year-over-year growth 2023-2028 (%)
    • 7.5 Rifampin - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Rifampin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Rifampin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Rifampin - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Rifampin - Year-over-year growth 2023-2028 (%)
    • 7.6 Rifabutin - Market size and forecast 2023-2028
      • Exhibit 64: Chart on Rifabutin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 65: Data Table on Rifabutin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 66: Chart on Rifabutin - Year-over-year growth 2023-2028 (%)
      • Exhibit 67: Data Table on Rifabutin - Year-over-year growth 2023-2028 (%)
    • 7.7 Others - Market size and forecast 2023-2028
      • Exhibit 68: Chart on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 69: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 70: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 71: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 7.8 Market opportunity by Product
      • Exhibit 72: Market opportunity by Product ($ billion)
      • Exhibit 73: Data Table on Market opportunity by Product ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 75: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 76: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 77: Chart on Geographic comparison
      • Exhibit 78: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.9 Japan - Market size and forecast 2023-2028
      • Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.10 Germany - Market size and forecast 2023-2028
      • Exhibit 107: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 108: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 109: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 110: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.11 China - Market size and forecast 2023-2028
      • Exhibit 111: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 112: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 113: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 114: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 115: Market opportunity by geography ($ billion)
      • Exhibit 116: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 117: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 119: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 120: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 121: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 122: Matrix on vendor position and classification
            • 12.3 Abbott Laboratories
              • Exhibit 123: Abbott Laboratories - Overview
              • Exhibit 124: Abbott Laboratories - Business segments
              • Exhibit 125: Abbott Laboratories - Key news
              • Exhibit 126: Abbott Laboratories - Key offerings
              • Exhibit 127: Abbott Laboratories - Segment focus
            • 12.4 Astellas Pharma Inc.
              • Exhibit 128: Astellas Pharma Inc. - Overview
              • Exhibit 129: Astellas Pharma Inc. - Product / Service
              • Exhibit 130: Astellas Pharma Inc. - Key news
              • Exhibit 131: Astellas Pharma Inc. - Key offerings
            • 12.5 Cipla Ltd.
              • Exhibit 132: Cipla Ltd. - Overview
              • Exhibit 133: Cipla Ltd. - Business segments
              • Exhibit 134: Cipla Ltd. - Key news
              • Exhibit 135: Cipla Ltd. - Key offerings
              • Exhibit 136: Cipla Ltd. - Segment focus
            • 12.6 Glenmark Pharmaceuticals Ltd.
              • Exhibit 137: Glenmark Pharmaceuticals Ltd. - Overview
              • Exhibit 138: Glenmark Pharmaceuticals Ltd. - Product / Service
              • Exhibit 139: Glenmark Pharmaceuticals Ltd. - Key offerings
            • 12.7 Hikma Pharmaceuticals Plc
              • Exhibit 140: Hikma Pharmaceuticals Plc - Overview
              • Exhibit 141: Hikma Pharmaceuticals Plc - Business segments
              • Exhibit 142: Hikma Pharmaceuticals Plc - Key offerings
              • Exhibit 143: Hikma Pharmaceuticals Plc - Segment focus
            • 12.8 Insmed Inc.
              • Exhibit 144: Insmed Inc. - Overview
              • Exhibit 145: Insmed Inc. - Product / Service
              • Exhibit 146: Insmed Inc. - Key offerings
            • 12.9 Johnson and Johnson
              • Exhibit 147: Johnson and Johnson - Overview
              • Exhibit 148: Johnson and Johnson - Business segments
              • Exhibit 149: Johnson and Johnson - Key news
              • Exhibit 150: Johnson and Johnson - Key offerings
              • Exhibit 151: Johnson and Johnson - Segment focus
            • 12.10 Lupin Ltd.
              • Exhibit 152: Lupin Ltd. - Overview
              • Exhibit 153: Lupin Ltd. - Product / Service
              • Exhibit 154: Lupin Ltd. - Key news
              • Exhibit 155: Lupin Ltd. - Key offerings
            • 12.11 Pfizer Inc.
              • Exhibit 156: Pfizer Inc. - Overview
              • Exhibit 157: Pfizer Inc. - Product / Service
              • Exhibit 158: Pfizer Inc. - Key news
              • Exhibit 159: Pfizer Inc. - Key offerings
            • 12.12 QIAGEN NV
              • Exhibit 160: QIAGEN NV - Overview
              • Exhibit 161: QIAGEN NV - Product / Service
              • Exhibit 162: QIAGEN NV - Key news
              • Exhibit 163: QIAGEN NV - Key offerings
            • 12.13 Sanofi SA
              • Exhibit 164: Sanofi SA - Overview
              • Exhibit 165: Sanofi SA - Business segments
              • Exhibit 166: Sanofi SA - Key news
              • Exhibit 167: Sanofi SA - Key offerings
              • Exhibit 168: Sanofi SA - Segment focus
            • 12.14 Sun Pharmaceutical Industries Ltd.
              • Exhibit 169: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 170: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 171: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.15 Teva Pharmaceutical Industries Ltd.
              • Exhibit 172: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 173: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 174: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 176: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.16 Viatris Inc.
              • Exhibit 177: Viatris Inc. - Overview
              • Exhibit 178: Viatris Inc. - Business segments
              • Exhibit 179: Viatris Inc. - Key news
              • Exhibit 180: Viatris Inc. - Key offerings
              • Exhibit 181: Viatris Inc. - Segment focus
            • 12.17 Zydus Lifesciences Ltd.
              • Exhibit 182: Zydus Lifesciences Ltd. - Overview
              • Exhibit 183: Zydus Lifesciences Ltd. - Business segments
              • Exhibit 184: Zydus Lifesciences Ltd. - Key offerings
              • Exhibit 185: Zydus Lifesciences Ltd. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 186: Inclusions checklist
                • Exhibit 187: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 188: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 189: Research methodology
                • Exhibit 190: Validation techniques employed for market sizing
                • Exhibit 191: Information sources
              • 13.5 List of abbreviations
                • Exhibit 192: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              nontuberculous mycobacterial infections market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis